| Index | S&P 500 | P/E | 39.51 | EPS (ttm) | 0.76 | Insider Own | 0.11% | Shs Outstand | 5.70B | Perf Week | 1.52% |
| Market Cap | 171.16B | Forward P/E | 10.38 | EPS next Y | 2.89 | Insider Trans | 1.69% | Shs Float | 5.69B | Perf Month | 5.70% |
| Enterprise Value | 222.66B | PEG | - | EPS next Q | - | Inst Own | 84.38% | Short Float | 2.64% | Perf Quarter | 21.73% |
| Income | 4.33B | P/S | 2.69 | EPS this Y | -5.27% | Inst Trans | 0.00% | Short Ratio | 4.04 | Perf Half Y | 11.22% |
| Sales | 63.70B | P/B | 2.00 | EPS next Y | -2.08% | ROA | 2.15% | Short Interest | 150.22M | Perf YTD | 20.60% |
| Book/sh | 15.00 | P/C | 14.63 | EPS next 5Y | -4.56% | ROE | 4.89% | 52W High | 30.44 -1.35% | Perf Year | 21.48% |
| Cash/sh | 2.05 | P/FCF | 15.58 | EPS past 3/5Y | -37.12% -3.51% | ROIC | 9.94% | 52W Low | 23.62 27.14% | Perf 3Y | -4.39% |
| Dividend Est. | 1.72 (5.73%) | EV/EBITDA | 16.50 | Sales past 3/5Y | -14.80% 8.48% | Gross Margin | 73.18% | Volatility | 1.72% 1.85% | Perf 5Y | -27.62% |
| Dividend TTM | 1.72 (5.73%) | EV/Sales | 3.50 | EPS Y/Y TTM | -46.10% | Oper. Margin | 26.72% | ATR (14) | 0.56 | Perf 10Y | -3.29% |
| Dividend Ex-Date | Nov 06, 2026 | Quick Ratio | 0.96 | Sales Y/Y TTM | 0.11% | Profit Margin | 6.80% | RSI (14) | 65.55 | Recom | 2.63 |
| Dividend Gr. 3/5Y | 2.44% 2.50% | Current Ratio | 1.27 | EPS Q/Q | -1.28% | SMA20 | 4.32% | Beta | 0.26 | Target Price | 29.17 |
| Payout | 225.88% | Debt/Eq | 0.78 | Sales Q/Q | 2.60% | SMA50 | 6.13% | Rel Volume | 0.85 | Prev Close | 30.42 |
| Employees | 75,000 | LT Debt/Eq | 0.74 | Earnings | Nov 03 | SMA200 | 12.54% | Avg Volume | 34.48M | Price | 30.03 |
| IPO Date | Jun 01, 1972 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 12.88% 4.41% | Net Debt/EBITDA | 4.61 | Volume | 29,364,915 | Change | -1.28% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-08-26 | Reiterated | Cantor Fitzgerald | Neutral | $27 → $28 |
| Oct-06-26 | Reiterated | Scotiabank | Sector Outperform | $33 |
| Sep-10-26 | Reiterated | HSBC | Hold | $28 → $30 |
| Aug-07-26 | Reiterated | Guggenheim | Buy | $35 → $31 |
| Jul-06-26 | Downgrade | HSBC | Buy → Hold | $29 → $28 |
| Jun-10-26 | Upgrade | RBC Capital | Underperform → Sector Perform | |
| May-27-26 | Reiterated | UBS | Neutral | $25 → $27 |
| May-14-26 | Reiterated | Wolfe Research | $25 → $26 | |
| Mar-17-26 | Reiterated | Morgan Stanley | Equal Weight | $28 → $27 |
| Mar-09-26 | Reiterated | BMO Capital | Outperform | $36 → $30 |
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 63,695 | 62,579 | 63,627 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 17,084 | 16,067 | 17,851 | — | — | — | — | — | — | |
| Gross Profit | 46,611 | 46,512 | 45,776 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 13,720 | 13,794 | 14,730 | — | — | — | — | — | — | |
| Research and Development | 11,051 | 10,437 | 10,822 | — | — | — | — | — | — | |
| Other Operating Expense | 4,821 | 4,874 | 5,286 | — | — | — | — | — | — | |
| Operating Income | 17,019 | 17,407 | 14,938 | — | — | — | — | — | — | |
| Interest Expense | 2,698 | 2,671 | 3,091 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -10,112 | -7,216 | -3,824 | — | — | — | — | — | — | |
| Net Income Before Taxes | 4,209 | 7,520 | 8,023 | — | — | — | — | — | — | |
| Income Taxes | -164 | -266 | -28 | — | — | — | — | — | — | |
| Consolidated Net Income | 4,332 | 7,771 | 8,031 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 4,373 | 7,787 | 8,051 | — | — | — | — | — | — | |
| Net Income | 4,332 | 7,771 | 8,031 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.76 | 1.36 | 1.42 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.76 | 1.36 | 1.42 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.76 | 1.36 | 1.41 | — | — | — | — | — | — | |
| EBITDA | 13,491 | 16,783 | 18,127 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 39.51 | 18.31 | 18.82 | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.69 | 2.26 | 2.36 | — | — | — | — | — | — | |
| Gross Margin | 73.18 | 74.33 | 71.94 | — | — | — | — | — | — | |
| Operating Margin | 26.72 | 27.82 | 23.48 | — | — | — | — | — | — | |
| Net Margin | 6.80 | 12.42 | 12.62 | — | — | — | — | — | — | |
| Shares Outstanding | 5,699 | 5,683 | 5,664 | — | — | — | — | — | — | |
| Market Capitalization | 171,141 | 141,507 | 150,266 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| BOURLA ALBERT | Chairman & CEO | Aug 12 '26 | Buy | 26.34 | 38,000 | 1,000,920 | 429,173 | Aug 12 |
| DAMICO JENNIFER B. | SVP & Controller | Aug 05 '26 | Sale | 25.40 | 3,278 | 83,261 | 28,611 | Aug 06 |
| BLAYLOCK RONALD E | Director | Aug 05 '26 | Buy | 25.46 | 39,231 | 998,821 | 66,938 | Aug 05 |
| Buckley Mortimer J | Director | Aug 05 '26 | Buy | 25.52 | 37,632 | 960,369 | 37,632 | Aug 05 |
| DAMICO JENNIFER B. | SVP & Controller | Jun 09 '26 | Sale | 25.70 | 2,000 | 51,400 | 31,397 | Jun 10 |
| McDermott Michael | Executive Vice President | Feb 25 '26 | Option Exercise | 33.82 | 37,925 | 1,282,624 | 114,534 | Feb 27 |
| Fonseca Lidia | Executive Vice President | Feb 25 '26 | Option Exercise | 33.82 | 56,888 | 1,923,952 | 101,579 | Feb 27 |
| SAHNI PAYAL | Executive Vice President | Feb 25 '26 | Option Exercise | 33.82 | 56,888 | 1,923,952 | 82,816 | Feb 27 |
| LANKLER DOUGLAS M | Executive Vice President | Feb 25 '26 | Option Exercise | 33.82 | 122,907 | 4,156,715 | 282,186 | Feb 27 |
| DAMICO JENNIFER B. | SVP & Controller | Feb 25 '26 | Option Exercise | 33.82 | 17,558 | 593,812 | 29,744 | Feb 27 |
| BOURLA ALBERT | Chairman & CEO | Feb 25 '26 | Option Exercise | 33.82 | 491,626 | 16,626,791 | 864,215 | Feb 27 |
| DAMICO JENNIFER B. | SVP & Controller | Mar 04 '25 | Sale | 25.93 | 2,500 | 64,825 | 11,850 | Mar 06 |
| LANKLER DOUGLAS M | Executive Vice President | Feb 27 '25 | Option Exercise | 31.31 | 156,914 | 4,912,977 | 309,790 | Mar 03 |
| DAMICO JENNIFER B. | SVP & Controller | Feb 27 '25 | Option Exercise | 31.31 | 22,416 | 701,845 | 31,063 | Mar 03 |
| SUSMAN SALLY | Executive Vice President | Feb 27 '25 | Option Exercise | 31.31 | 85,182 | 2,667,048 | 250,866 | Mar 03 |